Advertisement

Topics

Ambrilia Biopharma Inc. Company Profile

19:25 EST 11th December 2018 | BioPortfolio

Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases. Ambrilia’s product portfolio includes proprietary mid to early-stage products; an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first of which is late-stage and value-added, and promising anti-HIV treatments (PPL-100, SPC3). Ambrilia’s product candidates address unmet medical needs in the fields of oncology and infectious diseases where safe and effective therapies are needed, and which represent large market opportunities.

Location

1000 chemin du Golf
Verdun
Quebec
H3E 1H4
Canada

Contact

Phone: (514) 751-2003
Fax: (514) 751-2502
Email: cpanchal@ambrilia.com., rnaudin@ambrilia.com


News Articles [1369 Associated News Articles listed on BioPortfolio]

KBI Biopharma: How to stand out in the CMO space

KBI Biopharma is a CMO focused exclusively on biologics. Bernardo Estupinan-Gaisbauer, Vice President – Business Development at KBI Biopharma, discusses their strategy for partnering, and the challe...

Hillstream BioPharma looks forward to pre-IND discussion with FDA in Q4

Hillstream BioPharma CEO Randy Milby sits down with Proactive Investors' Christine Corrado at the BIO Investor Forum in San Francisco. Hillsteam BioPharma is developing targeted cancer therapeutic...

Prestige Biopharma And Alvogen Announce License And Supply Agreement To Commercialize Biosimilar

NewsPrestige BioPharma and Alvogen have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar in Central a...

#jobs #lifescience Director of Corporate Communications – Ph III Biopharma

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Director of Corporate Communications – Ph III Biopharma .MA-Lexington, ...

Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene

Tasly Biopharma paid $48 million in stock to buy out its China JV partner Transgene (P: TNG), which holds China rights to two Transgene products: T601, an oncolytic virus, and T101, a therapeutic vacc...

#jobs #lifescience BioPharm/BioTech

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: BioPharm/BioTech .MA-Cambridge, BioPharma/BioTech BIOPHARMA/BIOTECH Amgen, In...

How the US-Mexico trade deal could impact the biologics market

BioPharma-Reporter (BPR) discusses with Jennifer Fox (JF), co-chair of Brinks Gilson & Lioneâs biopharma practice group, the provisional detail revealed from the US administrationâs proposed trade d...

Biopharma Market: An Inside Look

Survey results reveal how slow-motion trends are driving biopharma growth

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Cardene® sr [PDL BioPharma, Inc.]

CARDENE® SR

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

Recombinate [Baxter Healthcare Corporation]

RECOMBINATE [Antihemophilic Factor (Recombinant)]

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Rethinking the Clinically Based Thresholds of TransCelerate BioPharma for Risk-Based Monitoring.

The quality of data from clinical trials has received a great deal of attention in recent years. Of central importance is the need to protect the well-being of study participants and maintain the inte...

Bicyclic bis-heteroaryl derivatives as inhibitors of the α-synuclein protein: a patent evaluation of WO2018138088A1.

Neurodegenerative diseases commonly present misfolding and aggregation of one or more proteins, including α-synuclein, β-amyloid and tau. Several research efforts have been made to develop therapeut...

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and ...

A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries

The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure. Restenosis has long been considered a ma...

Companies [147 Associated Companies listed on BioPortfolio]

Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases. Ambrilia’s product portfolio includes proprieta...

SAFE-BioPharma Association

SAFE-BioPharma Association (www.safe-biopharma.org) is the non-profit association that created and manages the SAFE-BioPharma® digital identity and signature standard for the ...

Kedrion Biopharma, Inc.

Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and pre...

Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-b...

SAFE-BioPharma Association, LLC

As part of the National Health Information Sharing and Analysis Center (NH-ISAC), SAFE-BioPharma Association, LLC [www.safe-biopharma.org] provides global, high-assurance identity...

More Information about "Ambrilia Biopharma Inc." on BioPortfolio

We have published hundreds of Ambrilia Biopharma Inc. news stories on BioPortfolio along with dozens of Ambrilia Biopharma Inc. Clinical Trials and PubMed Articles about Ambrilia Biopharma Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ambrilia Biopharma Inc. Companies in our database. You can also find out about relevant Ambrilia Biopharma Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record